As reported on November 19, 2026, a supply disruption affecting Sanofi’s Pompe disease treatments had lasted more than three months. Some patients had missed infusions, and Sanofi said shipping delays could interrupt treatment for some U.S. patients through the end of November.
Sanofi attributed the shortage of Lumizyme and Nexviazyme to issues at its manufacturing facility in Ireland. The U.S. Food and Drug Administration inspected the plant from January 12 to January 20, 2026, and found manufacturing violations involving two unrelated drugs. The agency sent Sanofi a warning letter on June 22 saying the company had not addressed an underlying failure to comply with manufacturing requirements. Sanofi said its work to address the FDA’s continuing concerns contributed to the disruption in Pompe treatment supplies.
Pompe disease weakens muscles and can affect breathing and the heart. Patients typically receive Sanofi’s enzyme-replacement treatments every two weeks. Monique Griffin, 51, said her next Lumizyme infusion was canceled after Sanofi notified her of a shipping delay. She fears that a prolonged interruption could worsen her condition.
Sanofi spokesperson Evan Berland said there were no drug-quality issues and that the company was prioritizing the most vulnerable patients. He advised patients to consult a health professional before switching treatments, saying the medicines are not interchangeable. The FDA said patient access was a priority and that it had offered Sanofi assistance.
Patients and families also questioned how they were informed. Pompe patient and advocate Ryan Colburn said many patients had not known about Sanofi’s manufacturing issues and could not prepare for a shortage. Sanofi said it had contacted patient groups, patients and clinicians as the extent of the disruption became clearer, and was continuing to provide updates.
